It is worth noting that in the VIALE-A trial, subgroup analysis demonstrated a superior CRc in Flt3-mutated AML patients receiving azacitidine plus venetoclax compared with azacitidine alone (72% vs. 36%, p = 0.02) [132]. The gene discussed is FLT3; the disease is acute myeloid leukemia.